

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-344-J (400.110US))

In the Application of:

McSwiggen et al.

Serial No.: 10/553,729

Filing Date: October 14, 2005

For: RNA Interference Mediated Inhibition of
Severe Acute Respiratory Syndrome
(SARS) Gene Expression Using Short
Interfering Nucleic Acid (siNA)



Examiner: TBA

Group Art Unit: TBA

Confirmation No.: TBA

TRANSMITTAL LETTER

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:

- a) Information Disclosure Statement;
- b) PTO Form PTO/SB/08a;
- c) PTO Form PTO/SB/08b;
- d) 13 Cited References;
- e) Return receipt postcard.


2. With respect to fees:

- a) A fee is not required at this time.
- b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on April 12, 2006.

Date: April 12, 2006

Respectfully submitted


Michael S. Greenfield
Registration No. 37,142

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-344-J (400.110US))

In the Application of:

McSwiggen et al.

Serial No.: 10/553,729

Filing Date: October 14, 2005

For: RNA Interference Mediated Inhibition of
Severe Acute Respiratory Syndrome
(SARS) Gene Expression Using Short
Interfering Nucleic Acid (siNA)



Examiner: TBA

Group Art Unit: TBA

Confirmation No.: TBA

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO Form PTO/SB/08a and PTO/SB/08b.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 12, 2006.

Date: April 12, 2006


Michael S. Greenfield

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

FOREIGN PATENT DOCUMENTS

1. PCT Patent No. WO 02/097114 A2, published December 5, 2002
2. PCT Patent No. WO 00/44895 A1, published August 3, 2000.
3. PCT Patent No. WO 2004/011647 A1, published February 5, 2004.
4. Abstract of Chinese Patent CN 1 458 281, published November 26, 2003.
5. Abstract of Chinese Patent CN 1 465 584, published January 7, 2004.

OTHER DOCUMENTS


1. Peiris, J.S. M. et al., "Coronavirus as a Possible Cause of Severe Acute Respiratory Syndrome", THE LANCET (NORTH AMERICAN EDITION), Vol. 361, April 8, 2003, pp. 1319-1325.
2. Ksiazek, Thomas G. et al., "A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, Vol. 348, No. 20, May 15, 2003, pp. 1953-1966.
3. Elbashir, Sayda M. et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in Drosophila Melanogaster Embryo Lysate", EMBO JOURNAL, OXFORD UNIVERSITY PRESS SURREY, GB, Vol. 20, No. 23, December 3, 2001, pp. 6877-6888.
4. Parrish, Susan et al., "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, Vol. 8, November, 2000, pp. 1077-1087.
6. Zhang, Renli et al., "Inhibiting Severe Acute Respiratory Syndrome-Associated Coronavirus by Small Interfering RNA", CHINESE MEDICAL JOURNAL, Vol. 116, No. 8, July 2003, pp. 1262-1264.
7. He, Ming-Liang et al., "Inhibition of SARS-Associated Coronavirus Infection and Replication by RNA Interference", JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, Vol. 290, No. 20, November 26, 2003, pp. 2665-2666.

8. International Search Report for PCT/US2004/011320, dated December 23, 2004.
9. International Preliminary Examination Report for PCT/US2004/011320, dated October 21, 2005.

Respectfully submitted,

Date: April 12, 2006

By:


Michael S. Greenfield
Reg. No. 37,142

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/553,729
Filing Date	October 14, 2005
First Named Inventor	James McSwiggen
Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	03-344-J (400.110US)

Sheet 1 of 1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³ "Number" ⁴ "Kind Code" ⁵ (if known)				
	1	WO 02/097114 A2	12/05/2002	Ribozyme Pharmaceuticals, Incorporation		
	2	WO 00/44895 A1	08/03/2000	Kreutzer, Roland		
	3	WO 2004/011647 A1	02/05/2004	Chiron Corporation		
	4	CN 1 458 281 Abstract	11/26/2003	Huanqiu Zhongjia Biological Science and Technology Co., Ltd.		
	5	CN 1 465 584 Abstract	01/07/2004	Beijing Jiaotong Univ.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/553,729
Filing Date	October 14, 2005
First Named Inventor	James McSwiggen
Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	03-344-J (400.110US)

Sheet

1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Peiris, J.S. M. et al., "Coronavirus as a Possible Cause of Severe Acute Respiratory Syndrome", THE LANCET (NORTH AMERICAN EDITION), Vol. 361, April 8, 2003, pp. 1319-1325.	
	2	Ksiazek, Thomas G. et al., "A Novel Coronavirus Associated with Sever Acute Respiratory Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, Vol. 348, No. 20, May 15, 2003, pp. 1953-1966.	
	3	Elbashir, Sayda M. et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in Drosophila Melanogaster Embryo Lysate", EMBO JOURNAL, OXFORD UNIVERSITY PRESS SURREY, GB, Vol. 20, No. 23, December 3, 2001, pp. 6877-6888.	
	4	Parrish, Susan et al., "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, Vol. 8, November, 2000, pp. 1077-1087.	
	5	Zhang, Renli et al., "Inhibiting Severe Acute Respiratory Syndrome-Associated Coronavirus by Small Interfering RNA", CHINESE MEDICAL JOURNAL, Vol. 116, No. 8, July 2003, pp. 1262-1264.	
	6	He, Ming-Liang et al., "Inhibition of SARS-Associated Coronavirus Infection and Replication by RNA Interference", JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, Vol. 290, No. 20, November 26, 2003, pp. 2665-2666.	
	7	International Search Report for PCT/US2004/011320, dated December 23, 2004.	
	8	International Preliminary Examination Report for PCT/US2004/011320, dated October 21, 2005.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.